PSMA radioligand therapy (PRLT) of metastatic castration-resistant prostate cancer: first results using the PSMA Inhibitor 617

被引：0
|
作者：
Kulkarni, Harshad [1 ]
Singh, Aviral [1 ]
Niepsch, Karin [1 ]
Schuchardt, Christiane [1 ]
Baum, Richard [1 ]
机构：
[1] Zent Klin Bad Berka, THERANOST Ctr Mol Radiotherapy & Mol Imaging PET, Bad Berka, Germany
来源：
JOURNAL OF NUCLEAR MEDICINE | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
139
引用
收藏
页数：2
相关论文
共 50 条
  • [1] PSMA Radioligand Therapy (PRLT) of Metastatic Castration-Resistant Prostate Cancer: Safety, Efficacy and Dosimetry using the PSMA Inhibitor 617
    Kulkarni, H. R.
    Schuchardt, C.
    Singh, A.
    Niepsch, K.
    Baum, R. P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S139 - S139
  • [2] Lu-PSMA-617 for metastatic castration-resistant Prostate Cancer
    Lorenz, Judith
    AKTUELLE UROLOGIE, 2022, 53 (02) : 106 - 106
  • [3] Efficacy and Safety of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients
    Yadav, Madhav Prasad
    Ballal, Sanjana
    Bal, Chandrashekhar
    Sahoo, Ranjit Kumar
    Damle, Nishikant Avinash
    Tripathi, Madhavi
    Seth, Amlesh
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (01) : 19 - 31
  • [4] Re-Rechallenge 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer
    Aggarwal, Piyush
    Gunasekaran, Vinisha
    Sood, Ashwani
    Kumar, Narendra
    Rathore, Yogesh
    Kumar, Rajender
    Mittal, Bhagwant Rai
    CLINICAL NUCLEAR MEDICINE, 2025, 50 (03) : 231 - 233
  • [5] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Groener, Daniel
    Cam Tu Nguyen
    Baumgarten, Justus
    Bockisch, Benjamin
    Davis, Karen
    Happel, Christian
    Mader, Nicolai
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Banek, Severine
    Mandel, Philipp
    Chun, Felix K. H.
    Tselis, Nikolaos
    Gruenwald, Frank
    Sabet, Amir
    EJNMMI RESEARCH, 2021, 11 (01)
  • [6] Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
    Daniel Groener
    Cam Tu Nguyen
    Justus Baumgarten
    Benjamin Bockisch
    Karen Davis
    Christian Happel
    Nicolai Mader
    Christina Nguyen Ngoc
    Jennifer Wichert
    Severine Banek
    Philipp Mandel
    Felix K. H. Chun
    Nikolaos Tselis
    Frank Grünwald
    Amir Sabet
    EJNMMI Research, 11
  • [7] Extended radioligand therapy with Lu-177-PSMA-617 in patients with advanced metastatic castration-resistant prostate cancer
    Mader, N.
    Baumgarten, J.
    Groener, D.
    Ngoc, C. Nguyen
    Davis, K.
    Banek, S.
    Tselis, N.
    Happel, C.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S489 - S489
  • [8] Intermittent Radioligand Therapy with 177Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer
    Mader, Nicolai
    Schoeler, Christina
    Pezeshkpour, Niloufar
    Klimek, Konrad
    Groener, Daniel
    Happel, Christian
    Tselis, Nikolaos
    Mandel, Philipp
    Gruenwald, Frank
    Sabet, Amir
    CANCERS, 2023, 15 (18)
  • [9] Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
    Sartor, Oliver
    de Bono, Johann
    Chi, Kim N.
    Fizazi, Karim
    Herrmann, Ken
    Rahbar, Kambiz
    Tagawa, Scott T.
    Nordquist, Luke T.
    Vaishampayan, Nitin
    El-Haddad, Ghassan
    Park, Chandler H.
    Beer, Tomasz M.
    Armour, Alison
    Perez-Contreras, Wendy J.
    DeSilvio, Michelle
    Kpamegan, Euloge
    Gericke, Germo
    Messmann, Richard A.
    Morris, Michael J.
    Krause, Bernd J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (12): : 1091 - 1103
  • [10] Promising 177Lu-PSMA-617 Therapy Results in Patients with Metastatic Castration-Resistant Prostate Cancer
    Brnjic, Antonio
    Frye, Sarah
    Botkin, Crystal
    Osman, Medhat
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62
12345